Compound ID | 1737
Bezlotoxumab, Zinplava
Class: Antibody
| Agent Type: | Natural product; Direct acting; Antibody; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Neutralizes toxins produced by Clostridioides difficile |
| Target Pathogen: | Active against Clostridioides difficile |
| Institute where first reported: | Medarex Inc and MassBiologics; Merck Sharp & Dohme |
| Year first mentioned: | 2009 |
| Highest development stage: | Approved by FDA in 2016 |
| Development status: | Approved |
| External links: | |
| Guide to Pharmacology: | bezlotoxumab |
| Citation: | https://www.nature.com/articles/s41429-020-0344-z |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.